Kura Oncology, Inc.
Moat Score — Kura Oncology, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Kura holds an exclusive University of Michigan license covering its menin-KMT2A chemistry and has secured Breakthrough Therapy Designation for ziftomenib, giving it a defensible, FDA-validated IP position in a genuinely novel mechanism, though it falls short of a 5 since no product is yet approved or commercialized. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Kura owns no manufacturing and relies entirely on third-party contract manufacturers; as a pre-revenue clinical-stage biotech it has no cost-based advantage over competitors and is purely an R&D cost center today. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Ziftomenib is not yet approved, so any future orphan-style pricing power in NPM1-mutant AML is still hypothetical; near-term, the company has no commercial pricing lever at all. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in small-molecule oncology drug development; value accrues from clinical data and regulatory approval, not from usage-driven network dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no approved product yet, there are no real prescriber or patient switching costs today; once (if) ziftomenib is approved, oncologist treatment-protocol inertia could create modest stickiness, but this is speculative. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The NPM1-mutant/KMT2A-rearranged AML population is a genuinely niche genetic subset, which limits the addressable market, but multiple well-funded competitors (Syndax, Biomea Fusion, Janssen) are racing into the same niche, undercutting any efficient-scale protection. |